Clinical Trials
16 trialsNCT06134232 2025-08-27
ProvONE
Dendreon
Phase 2 Recruiting
NCT03686683 2024-10-08
ProVent
Dendreon
Phase 3 Completed
NCT01727154 2019-08-19
PRIME
Dendreon
Terminated
NCT01306890 2019-06-07
PROCEED
Dendreon
Completed
NCT01487863 2019-03-19
Concurrent vs. Sequential Sipuleucel-T & Abiraterone Treatment in Men With Metastatic Castrate Resistant Prostate Cancer
Dendreon
Phase 2 Completed
NCT01981122 2018-10-24
A Study of Sipuleucel-T With Administration of Enzalutamide in Men With Metastatic Castrate-Resistant Prostate Cancer
Dendreon
Phase 2 Completed
NCT00779402 2018-01-29
PROTECT
Dendreon
Phase 3 Completed
NCT01338012 2017-06-05
mCRPC
Dendreon
Phase 2 Terminated
NCT01431391 2017-05-30
Sequencing of Sipuleucel-T and ADT in Men With Non-metastatic Prostate Cancer
Dendreon
Phase 2 Completed
NCT00715078 2017-05-23
To Evaluate Sipuleucel-T Manufactured With Different Concentrations of (PA2024) Antigen
Dendreon
Phase 2 Completed
NCT00901342 2017-05-23
Open Label Study of Sipuleucel-T in Metastatic Prostate Cancer
Dendreon
Phase 2 Completed
NCT01477749 2015-12-09
Sipuleucel-T Manufacturing Demonstration Study
Dendreon
Phase 2 Completed
NCT00715104 2015-05-04
NeoACT
Dendreon
Phase 2 Completed
NCT00005947 2010-11-01
Vaccine Therapy in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy
Dendreon
Phase 3 Completed
NCT01133704 2010-09-08
Immunotherapy With APC8015 (Sipuleucel-T, Provenge) for Asymptomatic, Metastatic, Hormone-Refractory Prostate Cancer
Dendreon
Phase 3 Completed
NCT00065442 2010-09-06
ProvengeĀ® (Sipuleucel-T) Active Cellular Immunotherapy Treatment of Metastatic Prostate Cancer After Failing Hormone Therapy
Dendreon
Phase 3 Completed